Archive

ASH 2015: Ernest Beutler Lecture Prize: Award-winners trace history of proteasome and its starring role in MM treatment: Interview with Alfred Goldberg, PhD, Professor of Cell Biology at Harvard Medical School, and Paul Richardson, MD, Professor of Medicine at the Dana-Farber Cancer Center

by Thomas R. Collins: Standing at the center of a decade and a half of stunning advancements in the treatment of multiple myeloma is the ubiquitin proteasome pathway… read more.

ASH 2015: Myeloma X (intensive) trial update: Professor Gordon Cook (Leeds Teaching Hospitals, UK) gives an update on Myeloma X and discusses the role of transplant in myeloma in the age of novel agents

ASH 2015 Video Interview by Esther Drain: Is oral as effective as IV or sub cutaneous administration? Professor Philippe Moreau (University Hospital, Nantes, France), Professor Gordon Cook (Leeds Teaching Hospitals, UK) and Professor Sagar Lonial (Emory University School of Medicine, Atlanta, USA) discuss whether the trend towards new oral agents for myeloma will mean a choice between efficacy and convenience… or in fact whether both can be achieved

ASH 2015: TOURMALINE: Professor Philippe Moreau (University Hospital, Nantes, France) discusses the Tourmaline study – ixazomib, lenalidomide, dexamethasone (iRd) in R/R myeloma, with opinions on the data from Professor Graham Jackson (NCCC, Newcastle Hospitals Trust, UK), Professor Gordon Cook (Leeds Teaching Hospitals, UK), Erik Low (Chief Executive Myeloma UK) and Dr Shaji Kumar (Mayo Clinic, Rochester, USA)

Ixazomib improves progression-free survival across subgroups by Thomas R. Collins: The oral proteasome inhibitor (PI) ixazomib with lenalidomide and dexamethasone (IRd) performed well versus placebo plus lenalidomide and… read more.

ASH 2015 Video Interview by Esther Drain: Erik Low (Chief Executive Myeloma UK), Professor Graham Jackson (NCCC, Newcastle Hospitals Trust, UK) and Professor Gordon Cook (Leeds Teaching Hospitals, UK) discuss how and when we might expect our patients to have access to the therapies now available to US myeloma patients

ASH 2015: Clinical discussant in this ASH/FDA session, Professor Paul Richardson (Harvard medical School, Boston, USA), discusses the clinical relevance of the new oral proteazome inhibitor ixazomib and two new monoclonal antibodies daratumumab and elotuzumab approved in the last few weeks by the FDA

Experts try to provide clarity in dizzying myeloma landscape by Thomas R. Collins: There’s no doubt that the bonanza of new multiple myeloma therapies is a blessing to… read more.

ASH 2015: Interview with Professor Sagar Lonial (Emory University School of Medicine, Atlanta, GA, USA) gives a flavour of the excitement generated at ASH

ASH 2015 proved to be all that we’d hoped for! We’ve witnessed unprecedented change in multiple myeloma with CR and VGPR percentages higher than ever… and most of this… read more.

ASH 2015: Investigators update results on key carfilzomib studies: ENDEAVOR and ASPIRE

by Thomas R. Collins: A subgroup analysis of data from the ENDEAVOR trial, comparing carfilzomib and dexamethasone (Kd) to bortezomib and dexamethasone (Vd) — shows improved progression-free survival (PFS)… read more.

ASH 2015: Ixazomib shows promise in variety of settings, according to early trial results

by Thomas R. Collins: Fresh off its approval in the U.S. in the relapsed/refractory setting of multiple myeloma, ixazomib continues to be examined in other patient pools, with… read more.

ASH 2015: Trials exploring new settings for monoclonal antibodies in MM

by Thomas R. Collins: Trials are continuing to explore potential new settings for daratumumab and elotuzumab, two monoclonal antibodies that were recently approved for use in multiple myeloma… read more.

IMV 2015: Newly diagnosed multiple myeloma, elderly patients: Professor Gareth Morgan, (Little Rock, USA) and Professor Paul Richardson, (Boston, USA) discuss managing older patients with MM

The majority of patients presenting with MM are elderly and pose a considerable clinical challenge in terms of disease burden and comorbidities compared with their younger counterparts. A… read more.

IMV 2015: Activated pathways leading to high-risk myeloma: Professor Gareth Morgan, UAMS Myeloma Institute, Arkansas, USA discusses how our understanding of the biological pathways in MM has progressed recently.

Gene expression profiling (GEP) is currently the best approach for defining risk in multiple myeloma (MM). Mutation detection may be used for improving risk stratification and providing additional… read more.